EXELIXIS, INC. EXEL
- zanzalintinib — Colorectal Cancer NDA Submitted
- zanzalintinib — Non-Clear Cell Renal Cell Carcinoma Phase 3
- zanzalintinib — Renal Cell Carcinoma Phase 3
- zanzalintinib — Neuroendocrine Tumors Phase 2
- zanzalintinib — Meningioma Phase 2
- zanzalintinib — Non-Small Cell Lung Cancer Phase 1
- zanzalintinib — Castration-Resistant Prostate Cancer Phase 2
- zanzalintinib — Bladder Cancer Phase 1